[1]
|
Handoko, M.L., de Man, F.S., Allaart, C.P., Paulus, W.J., Westerhof, N. and Vonk-Noordegraaf, A. (2010) Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: Lessons from the left heart. European Respiratory Review, 19, 72-82.
doi:10.1183/09059180.00007109
|
[2]
|
Ghofrani, H.A., Morrell, N.W., Hoeper, M.M., et al. (2010) Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. American Journal of Respiratory and Critical Care Me- dicine, 182, 1171-1177.
doi:10.1164/rccm.201001-0123OC
|
[3]
|
Perros, F., Montani, D., Dorfmuller, P., et al. (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 178, 81-88. doi:10.1164/rccm.200707-1037OC
|
[4]
|
Schermuly, R.T., Dony, E., Ghofrani, H.A., et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. The Journal of Clinical Investigation, 115, 2811-2821. doi:10.1172/JCI24838
|
[5]
|
Hoeper, M.M., et al. (2011) Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IM- PRES). Data presented at the European Respiratory Society (ERS) Annual Congress. Abstract No. 413.
|
[6]
|
Druker, B.J., Guilhot, F., O’Brien, S.O., et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine, 355, 2408-2417.
|
[7]
|
Gerogianni, I., Kouloumenta, V., Zigoulis, P., et al. (2006) A 50-year-old man with pleural effusion and chronic myelogenous leukemia. The Internet Journal of Pulmonary Medicine, 6, 115. doi:10.5580/115
|
[8]
|
Kelly, K., Swords, R., Mahalingam, D., Padmanabhan, S. and Giles, F.J. (2009) Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Targeted Oncology, 4, 99-105.
|
[9]
|
Bergeron, A., Rea, D., Levy, V., et al. (2007) Lung abnormalities after desatinib treatment for chronic myeloid leukemia. American Journal of Respiratory and Critical Care Medicine, 176, 814-818.
doi:10.1164/rccm.200705-715CR
|
[10]
|
Hoeper, M.M., Barst, R.J., Chang, H.J., et al. (2012) Imatinib safety and efficacy: interim analysis of IMPRES extension study in patients with pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 185, A2495.
|
[11]
|
Young, D. (2012) Scrip intelligence.
http://www.scripintelligence.com/home/Novartis-yanks-imatinib-PAH-NDA-FDA-wants-more-data-cancels-AdCom-334095
|
[12]
|
Montani, D., Bergot, E., Gunther, S., et al. (2012) Pulmonary arterial hypertension in patient treated by dasatinib. Circulation, 125, 2128-2137
|